Sign in
WithdrawnPhase 1/2

Low-dose IL-2 in Established T1D - The "PROREG" Study

Key facts

Who runs it
Jay S. Skyler
Where
Miami, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
Jun 2023
Expected to end
Dec 2028
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ILT-101 (Aldesleukin; IL-2)
  • Treatment-Placebo Arm
  • Placebo Arm
Record updated
22 May 2024
Why it stopped
Funding withdrawal and COVID-19 environment.

Who can take part

Age
8 years to 21 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • 8-21 years of age
  • T1D, demonstrated by at least one islet autoantibody
  • T1D duration 4-12 months at the time of the first dose
  • Peak stimulated C-peptide >0.2 nmol/L during a 4-hour MMTT

Who cannot take part

  • Treatment with oral anti-diabetic agents
  • Illnesses that would preclude use of low-dose IL-2

Where in United States

  • Diabetes Research Institute, University of Miami Miller School of MedicineMiami, United States

About the trial

What the trial wants to find out

Randomized, controlled, double-blinded, multicenter, phase I/II clinical trial to evaluate the safety of low-dose IL-2 and determine whether low-dose IL-2 therapy for one year, can prevent further loss of beta-cell function in patients with established T1D, (primary outcome). The study will carefully examine various effects of low-dose IL-2 on the immune system in patients with T1D, including effects on Treg and other cell subsets, and disease-specific autoimmune responses.

The 3 groups in the trial

  • Treatment ArmExisting treatment, for comparison

    ILT-101 (Aldesleukin; IL-2), 0.5 million IU/m2 (up to a maximum of 1 million IU), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for two years.

    Treatment: ILT-101 (Aldesleukin; IL-2)

  • Treatment-Placebo ArmTreatment being tested

    Participants in this group will receive study drug ILT-101 for one year, and then placebo for the second year.

    Treatment: ILT-101 (Aldesleukin; IL-2) and Treatment-Placebo Arm

  • PlaceboPlacebo, for comparison

    Participants in this group will receive a placebo injection for two years.

    Treatment: Placebo Arm

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double Blind, Phase I/II Trial of Low-Dose Interlekin-2 Immunotherapy in Established Type 1 Diabetes
Record updated
22 May 2024